SCHEMBL4280067

SCHEMBL4280067

CCOc1ccc(Br)cc1-c1cc(Nc2ccc(F)cc2)ncn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.58
CYP2D6 P10635 3/20 0.58
CYP2C19 P33261 3/20 0.58
USP2 O75604 2/20 0.58
ALDH1A1 P00352 2/20 0.58
ALOX15 P16050 2/20 0.58
HSD17B10 Q99714 2/20 0.58
CLK4 Q9HAZ1 2/20 0.58
LMNA P02545 1/20 0.58
AGPAT2 O15120 13/20 0.57
CYP3A4 P08684 2/20 0.54
MAPK1 P28482 2/20 0.54
HPGD P15428 1/20 0.54
EGFR P00533 3/20 0.49
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
GLA P06280 1/20 0.47
CYP2C9 P11712 1/20 0.47
KMT2A Q03164 1/20 0.47
ERBB3 P21860 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288289 0.93 AGPAT2 (0.61) CYP1A2CYP2D6CYP2C19USP2ALDH1A1
SCHEMBL4281823 0.89 AGPAT2 (0.72) AGPAT2
SCHEMBL4290421 0.88 AGPAT2 (0.54) CYP1A2CYP2D6CYP2C19USP2ALDH1A1
SCHEMBL4285127 0.85 AGPAT2 (0.58) AGPAT2CCNT1CDK9
SCHEMBL15486198 0.74 CDK9 (0.52) CYP1A2CYP2D6CYP2C19USP2ALDH1A1
SCHEMBL4286118 0.74 AGPAT2 (0.49) AGPAT2HPGDEGFRMEN1KMT2A
SCHEMBL8515978 0.74 CDK9 (0.66) CYP1A2CYP2D6CYP2C19USP2ALDH1A1
SCHEMBL4114712 0.73 CYP1A2 (1.00) CYP1A2CYP2D6CYP2C19USP2ALDH1A1
SCHEMBL15490011 0.73 USP2 (0.58) CYP1A2CYP2D6CYP2C19USP2ALDH1A1
SCHEMBL15487221 0.73 USP2 (0.58) CYP1A2CYP2D6CYP2C19USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US claimed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT CYP1A2 4325/4885CYP2D6 3689/4885CYP2C19 4472/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT CYP1A2 4519/4885CYP2D6 4317/4885CYP2C19 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.